Stifel Maintains Buy Rating on Mirum Pharmaceuticals, Sets $156 Target
Stifel maintained its Buy rating on Mirum Pharmaceuticals and a $156 price target. The target implies 95.1% upside from the October 14 close of $79.96.
Stifel maintained its Buy rating on Mirum Pharmaceuticals and a $156 price target. The target implies 95.1% upside from the October 14 close of $79.96.